KU 2019 Post San Antonio Breast Cancer Review
A

46 y/o F With Grade 2, 2.5 cm, NO ER+ Left BC / 40 y/o Premenopausal Woman With 5.5cm, Node Negative Grade IIDC / 48 y/o BRCA 2 Mutation Carrier With T2NO ER/PR+/HER2- BC

By KU 2019 Post San Antonio Breast Cancer Review FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
By KU 2019 Post San Antonio Breast Cancer Review FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
17 views
March 12, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
03:40
Integrity Continuing Education

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …

Feat. A. Bardia
17:39
Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
10:27
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…

Feat. S. Tolaney, H. Rugo
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
05:43
Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
50:59
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"

Feat. S. Tolaney, H. Rugo
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
07:18
V.K. Gadi

The Role of ctDNA as a Surveillance Approach in HR+/HER2- eBC

24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
07:23
Total Health

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan
24:10
Keck School of Medicine of USC

CDK4/6 Inhibitors in Breast Cancer: 2024 Update

Feat. R. O'Regan
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
28:23
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Anthracyclines for Early Stage Breast Cancer - Do They Still Have a …

Feat. V. Borges